ViiV Healthcare announces £3 million global fund to research the impact of COVID-19 on the HIV community and fill gaps in prevention, treatment and care during the pandemic.

London, 27 April 2020 – ViiV Healthcare, the global specialist HIV company majority owned by GSK, with Pfizer Inc. and Shionogi Limited as shareholders, today announced the creation of the Global HIV and COVID-19 Emergency Response Fund. The £3 million fund will make available critical financial resources for research projects to study the medical and scientific impact COVID-19 is having on people living with HIV and community-based grants to help address specific challenges to the HIV community created by the global pandemic.